Grand Brilliance Group Holdings Limited (8372) AI Stock Analysis

• Market Cap: HK$94.40M
• Dividend Yield: 2.17%
• Average Volume (3M): 135.00K
• Price to Earnings (P/E): 10.0
• Beta (1Y): 0.11
• Revenue Growth: -3.17%
• EPS Growth: 8.16%
• Country: HK
• Employees: 50
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Distribution
• EPS (TTM): <0.01
• Shares Outstanding: 800,000,000
• 10 Day Avg. Volume: 280,000
• 30 Day Avg. Volume: 135,000
• PEG Ratio: -0.87
• Price to Book (P/B): 0.89
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 10.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 76 Outperform
• Price Target: ―

Grand Brilliance Group Holdings Limited demonstrates robust financial stability with strong equity and low debt levels, supporting its resilience and operational efficiency. The positive technical indicators suggest upward momentum, enhancing its stock appeal. However, there is room for improvement in cash flow generation and net profit margins. The valuation is fair with a moderate P/E ratio and a decent dividend yield, making the stock a balanced investment option with potential for growth.

Grand Brilliance Group Holdings Limited Business Overview & Revenue Model

Company Description

Grand Brilliance Group Holdings Limited (8372) is a company based in Hong Kong, primarily engaged in the provision of medical devices and related services. The company focuses on offering a wide range of medical equipment, including diagnostic and therapeutic devices, to healthcare providers and facilities. Their products and services cater to various medical specialties, ensuring high-quality healthcare delivery across the region.

How the Company Makes Money

Grand Brilliance Group Holdings Limited generates revenue through the sale and distribution of medical devices and equipment. The company collaborates with healthcare providers, hospitals, and clinics to supply essential medical products, ensuring they meet the demands of the healthcare sector. Revenue streams include direct sales of equipment, long-term supply contracts, and maintenance services. Key partnerships with manufacturers and healthcare institutions further bolster their market position and contribute to their earnings.

Grand Brilliance Group Holdings Limited Financial Statement Overview

Summary

Grand Brilliance Group Holdings Limited presents a solid financial position with strong equity ratios and minimal debt, indicating stability and financial flexibility. However, there are areas for improvement, particularly in cash flow generation and net profit margins, which have shown some pressure. The company's revenue growth and operational efficiency are commendable, though continued focus on margin improvement and cash flow management will be crucial for sustaining financial health and shareholder value.

Income Statement

The company demonstrates solid revenue growth with a Revenue Growth Rate of 6.78% from 2023 to 2024 and maintains a strong Gross Profit Margin of 51.20%. However, the Net Profit Margin has slightly decreased to 9.59% from the prior year's 9.86%, indicating some pressure on profitability. The EBIT Margin of 6.41% suggests operational efficiency, though it has declined from the previous year. Overall, the income statement shows stability with room for improvement in net profit margins.

Balance Sheet

The balance sheet is robust with a high Equity Ratio of 90.27%, indicating a strong equity base relative to total assets. The Debt-to-Equity Ratio is low at 0.01, reflecting minimal leverage and suggesting financial stability. Return on Equity is commendable at 7.60%, indicating effective use of equity to generate profits. The balance sheet reflects strong financial health with low debt levels and efficient equity utilization.

Cash Flow

The cash flow statement shows a decline in Operating Cash Flow from HK$12.66M to HK$6.72M, indicating reduced cash generation from operations. Free Cash Flow has also declined, though it remains positive at HK$4.91M. The Free Cash Flow to Net Income Ratio is 0.63, suggesting adequate, but declining, cash flow relative to net income. Despite these challenges, the company maintains positive free cash flow, which is a strength but highlights the need for improving operational cash generation.

Breakdown	TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement
Total Revenue	82.29M	81.90M	76.70M	71.98M	70.24M	67.23M
Gross Profit	42.01M	41.94M	39.51M	36.35M	33.62M	36.37M
EBITDA	5.32M	13.20M	14.09M	9.87M	12.91M	14.79M
Net Income	8.45M	7.86M	7.56M	4.05M	7.86M	9.57M
Balance Sheet
Total Assets	116.13M	114.50M	115.25M	110.32M	112.01M	104.89M
Cash, Cash Equivalents and Short-Term Investments	66.48M	60.47M	61.86M	55.74M	70.26M	70.64M
Total Debt	4.20M	1.43M	4.45M	4.48M	4.87M	811.00K
Total Liabilities	11.50M	11.22M	16.58M	16.82M	18.96M	16.41M
Stockholders Equity	104.77M	103.33M	98.67M	93.51M	93.05M	88.48M
Cash Flow
Free Cash Flow	9.28M	4.91M	12.60M	-4.12M	5.62M	21.41M
Operating Cash Flow	10.11M	6.72M	12.66M	-3.33M	6.01M	21.63M
Investing Cash Flow	646.00K	-395.00K	-510.00K	-3.96M	-82.00K	623.00K
Financing Cash Flow	-5.67M	-7.42M	-6.40M	-7.58M	-6.36M	-5.55M

Grand Brilliance Group Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.12
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8372, the sentiment is Positive. The current price of 0.12 is above the 20-day moving average (MA) of 0.12, above the 50-day MA of 0.12, and above the 200-day MA of 0.10, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 52.81 is Neutral, neither overbought nor oversold. The STOCH value of 62.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8372.

Grand Brilliance Group Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
8372	76 Outperform	HK$94.40M	10.00	8.84%	2.17%	-3.17%	8.16%
Sector *	60 Neutral	HK$16.95B	5.65	-7.44%	2.87%	11.55%	-28.15%
8196	47 Neutral	HK$43.25M	―	-9.50%	―	-58.07%	-303.40%
8137	47 Neutral	HK$7.65B	―	-9.66%	―	-44.43%	-281.08%
8186	44 Neutral	HK$56.36M	235.29	0.88%	―	8.34%	―
8081	40 Underperform	HK$159.84M	―	-30.23%	―	5.79%	-780.00%
8056	34 Underperform	HK$33.46M	0.70		―	-68.00%	25.80%